Burgeoning Nanotechnology for Diabetic Wound Healing: A Novel Approach to the Future ^†

Diabetes mellitus (DM) is a widespread, long-term illness recognised as elevated blood sugar. Infection, inadequate blood flow, neuropathy and insufficient proliferative and cytokine signalling slow down wound healing in diabetics. Recent research has shown that the majority of wound treatments that are currently on the market are not sufficient to meet patients’ needs. Advancements in nanotechnology can help researchers to establish new therapeutic methods or improve existing ones. Nanodrug delivery systems, in particular, have emerged as a major player in the area of dermal restoration due to their slow drug release and abilities to tether bioactive components to the targeted area and dramatically improve the effectiveness of medication. Manufactured agents in the field of nanotherapy, such as nanoparticles and nanoscafolds, have recently shown promise for use in the management of diabetic wounds. Nanoparticles used in medicine have a large surface area relative to their size. Because of this, they have a better chance of interacting with living things and entering wounds. They work effectively in the slow, localised delivery of drugs that stimulate cell-to-cell communication, proliferation, blood vessel formation, signalling, and biomolecule production during wound healing. One or more therapeutic molecules can be released into the intended site slowly over time using nanoparticles. The promising results seen with nanoparticulate systems indicate that research into this technology’s capabilities will expand in the near future, expanding nanotechnology’s substantial medical benefits. Focusing on diabetic wounds, we evaluated the viability and efficacy of the most recently developed nanotechnology-based medications. In this article, we scrutinise the unmet needs of the wound-healing field, as well as the future directions of the currently available technologies, while also discussing novel approaches that can advance the field.